Arunasri Kelleti, MD
Internal Medicine · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 4 carriers
- Office
- 1
- Since medical school
- 27 years
- Graduated 1999
Offices
1 location · Indian Health Center of Santa Clara Valley · 37 clinicians in this group
Looking this up.
Hospitals listed: 059517 · 753106 · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
16 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kelleti’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A99796 · Current
Licensed to practise in California · since 2007 · expires 2028-08-31 · University of Health Sciences, Vijayawada, Guntur Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$3,114
Medicare paid this office $3,114 for 82 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Sarscv2 vac 30mcg trs-suc im | 16 | $1,350 | $84 |
| Admn sarscov2 vacc 1 dose | 16 | $834 | $52 |
| Hemoglobin a1c level | 52 | $312 | $5 |
Who their Medicare patients are
82 Original Medicare patients in 2024. Average age 73 · Women 67% · Health risk score 0.99. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Diabetes 72% · Coronary heart disease 18% · Chronic kidney disease 15%.
The office billed $3,980, Medicare allowed $3,200 and paid $3,114; for 130 services of 9 kinds; $1,784 of it was for drugs given in the office and $1,330 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 82 | 130 | 73 | 0.99 | $3,980 | $3,114 |
| 2023 | 24 | 34 | 72 | 1.24 | $1,010 | $479 |
| 2022 | 29 | 35 | 71 | 0.86 | $3,450 | $1,931 |
| 2014 | 20 | 32 | 68 | 0.76 | $7,285 | $1,412 |
| 2013 | 19 | 27 | 68 | 0.92 | $5,167 | $965 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Hemoglobin a1c level | 16 | $162 | $10 |
2022: 1 service
| Short return visit (20+ min) | 14 | $990 | $58 |
2014: 1 service
| Short return visit (20+ min) | 18 | $1,217 | $49 |
2013: 1 service
| Short return visit (20+ min) | 12 | $458 | $29 |
Medicaid work
$763,353 in 2024
Medicaid paid $763,353 for 11,044 billed services this clinician did in 2024, up to 373 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 2,889 | $651,325 |
| Short return visit (20+ min) | 3,040 | $41,628 |
| Return visit (30+ min) | 1,079 | $20,717 |
| Short return visit | 1,335 | $13,845 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 253 | $7,540 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 405 | $3,846 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 112 | $3,453 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 167 | $2,753 |
| Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years | 36 | $2,551 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years | 69 | $2,347 |
| Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years | 40 | $2,330 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | 124 | $2,166 |
| 2024 | 11,044 | 25 | 373 | $763,353 |
| 2023 | 3,714 | 11 | 133 | $282,815 |
| 2022 | 3,198 | 6 | 134 | $248,859 |
| 2021 | 3,955 | 7 | 150 | $334,081 |
| 2020 | 4,122 | 8 | 124 | $333,433 |
| 2019 | 653 | 6 | 101 | $52,549 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 1,274 | $274,506 |
| Short return visit (20+ min) | 1,428 | $4,947 |
| Return visit (30+ min) | 387 | $1,644 |
| Short return visit | 409 | $1,128 |
| Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use | 60 | $311 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 31 | $80 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 65 years and older | 22 | $70 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 23 | $70 |
| Hemoglobin A1C level | 40 | $49 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 20 | $7 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | 20 | $4 |
2022
| Clinic visit/encounter, all-inclusive | 1,180 | $241,401 |
| Short return visit (20+ min) | 1,008 | $3,410 |
| Short return visit | 605 | $2,066 |
| Return visit (30+ min) | 359 | $1,852 |
| Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use | 19 | $80 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 27 | $50 |
2021
| Clinic visit/encounter, all-inclusive | 1,584 | $326,628 |
| Short return visit (20+ min) | 970 | $3,157 |
| Short return visit | 1,078 | $2,752 |
| Return visit (30+ min) | 240 | $1,452 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 22 | $52 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 32 | $40 |
| Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only | 29 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 1,634 | $328,440 |
| Short return visit (20+ min) | 1,642 | $3,865 |
| Short return visit | 504 | $637 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 65 | $370 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 16 | $100 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 36 | $20 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 192 | $0 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 33 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 256 | $51,786 |
| Short return visit (20+ min) | 287 | $539 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 19 | $123 |
| Short return visit | 39 | $81 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 25 | $20 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 27 | $0 |
Drugs they prescribed that Part D paid
$374,032
Pharmacies billed $374,032 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (32 of 3,126) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%. Long-acting opioids: 38% of their opioid prescriptions.
2,781 generic and fewer than 11 brand-name prescriptions · $374,032 in drug cost · 56 antibiotic prescriptions to 27 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 44 | $67,549 | $1,535 |
| Januvia | 60 | $65,621 | $1,094 |
| Eliquis | 27 | $48,722 | $1,805 |
| Rybelsus | 29 | $40,156 | $1,385 |
| Ozempic | 25 | $31,084 | $1,243 |
See all 61 drugs
| Jardiance | 44 | $67,549 | $1,535 |
| Januvia | 60 | $65,621 | $1,094 |
| Eliquis | 27 | $48,722 | $1,805 |
| Rybelsus | 29 | $40,156 | $1,385 |
| Ozempic | 25 | $31,084 | $1,243 |
| Trulicity | 12 | $23,555 | $1,963 |
| Tradjenta | 16 | $22,578 | $1,411 |
| Basaglar Kwikpen U-100 | 11 | $2,693 | $245 |
| Gabapentin | 107 | $2,638 | $25 |
| Atorvastatin | 261 | $1,868 | $7 |
| Rosuvastatin | 45 | $1,788 | $40 |
| Omeprazole | 164 | $1,613 | $10 |
| Pregabalin | 45 | $1,442 | $32 |
| Losartan | 173 | $1,289 | $7 |
| Albuterol Sulfate Hfa | 44 | $1,191 | $27 |
| Metformin | 188 | $1,147 | $6 |
| Diclofenac | 38 | $1,122 | $30 |
| Telmisartan | 23 | $1,108 | $48 |
| Amlodipine Besylate | 287 | $1,106 | $4 |
| Levothyroxine | 72 | $797 | $11 |
| Duloxetine | 15 | $728 | $49 |
| Mirtazapine | 15 | $656 | $44 |
| Oxybutynin Chloride Er | 19 | $625 | $33 |
| Fluticasone Propionate | 73 | $600 | $8 |
| Pravastatin | 54 | $586 | $11 |
| Metoprolol | 52 | $573 | $11 |
| Oxybutynin Chloride | 14 | $542 | $39 |
| Famotidine | 44 | $479 | $11 |
| Tamsulosin | 35 | $352 | $10 |
| Montelukast | 20 | $349 | $17 |
| Acetaminophen-Codeine | 14 | $334 | $24 |
| Lisinopril | 59 | $328 | $6 |
| Levetiracetam | 20 | $324 | $16 |
| Baclofen | 29 | $324 | $11 |
| Propranolol | 11 | $318 | $29 |
| Pantoprazole | 27 | $313 | $12 |
| Glipizide Er | 19 | $311 | $16 |
| Metformin Hcl Er | 27 | $311 | $12 |
| Alendronate | 35 | $257 | $7 |
| Chlorthalidone | 17 | $219 | $13 |
| Nitrofurantoin Mono-Macro | 32 | $216 | $7 |
| Sertraline | 41 | $213 | $5 |
| Methadone | 12 | $200 | $17 |
| Hydrochlorothiazide | 69 | $194 | $3 |
| Ezetimibe | 12 | $191 | $16 |
| Atenolol | 33 | $187 | $6 |
| Clotrimazole | 13 | $170 | $13 |
| Hydralazine | 17 | $157 | $9 |
| Glipizide | 27 | $156 | $6 |
| Isosorbide Mononitrate Er | 14 | $142 | $10 |
| Trazodone | 13 | $127 | $10 |
| Clopidogrel | 15 | $115 | $8 |
| Pioglitazone | 11 | $101 | $9 |
| Metoprolol | 26 | $93 | $4 |
| Benazepril | 15 | $83 | $6 |
| Furosemide | 15 | $82 | $5 |
| Carvedilol | 11 | $68 | $6 |
| Hydroxyzine | 13 | $67 | $5 |
| Simvastatin | 28 | $63 | $2 |
| Cyclobenzaprine | 19 | $58 | $3 |
| Meloxicam | 16 | $25 | $2 |
Year by year
| 2024 | 3,126 | 250 | 1% (32) | None | $374,032 |
| 2023 | 1,936 | 193 | 1% (23) | None | $272,455 |
| 2022 | 1,323 | 149 | None | None | $174,447 |
| 2021 | 902 | 101 | None | None | $115,200 |
| 2020 | 635 | 68 | None | None | $42,568 |
| 2019 | 275 | 35 | None | 9% | $10,129 |
| 2018 | 290 | 39 | None | 20% | $11,618 |
| 2017 | 862 | 115 | 1% (11) | None | $58,885 |
| 2016 | 1,082 | 112 | 4% (44) | 16% | $81,754 |
| 2015 | 958 | 126 | 4% (35) | None | $41,646 |
| 2014 | 248 | 53 | None | 16% | $8,239 |
| 2013 | 67 | 23 | None | 24% | $3,743 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 42 drugs
| Januvia | 55 | $72,846 | $1,324 |
| Jardiance | 23 | $42,241 | $1,837 |
| Trulicity | 21 | $36,739 | $1,749 |
| Eliquis | 15 | $22,445 | $1,496 |
| Rybelsus | 13 | $12,587 | $968 |
| Atorvastatin | 160 | $3,343 | $21 |
| Basaglar Kwikpen U-100 | 11 | $2,864 | $260 |
| Losartan | 100 | $2,758 | $28 |
| Amlodipine Besylate | 163 | $2,600 | $16 |
| Gabapentin | 77 | $2,508 | $33 |
| Metformin | 123 | $2,474 | $20 |
| Pregabalin | 29 | $2,307 | $80 |
| Omeprazole | 93 | $1,925 | $21 |
| Levothyroxine | 58 | $1,580 | $27 |
| Albuterol Sulfate Hfa | 37 | $1,372 | $37 |
| Ventolin Hfa | 16 | $1,005 | $63 |
| Oxybutynin Chloride Er | 16 | $924 | $58 |
| Tamsulosin | 24 | $776 | $32 |
| Oxybutynin Chloride | 20 | $712 | $36 |
| Lisinopril | 43 | $697 | $16 |
| Benazepril | 16 | $677 | $42 |
| Rosuvastatin | 21 | $668 | $32 |
| Baclofen | 20 | $645 | $32 |
| Diclofenac | 21 | $587 | $28 |
| Simvastatin | 20 | $586 | $29 |
| Fluticasone Propionate | 30 | $585 | $20 |
| Pravastatin | 20 | $584 | $29 |
| Nitrofurantoin Mono-Macro | 33 | $573 | $17 |
| Metoprolol | 29 | $518 | $18 |
| Alendronate | 29 | $516 | $18 |
| Metoprolol | 23 | $431 | $19 |
| Atenolol | 13 | $368 | $28 |
| Famotidine | 21 | $329 | $16 |
| Metformin Hcl Er | 14 | $306 | $22 |
| Sertraline | 20 | $282 | $14 |
| Hydrochlorothiazide | 37 | $230 | $6 |
| Glipizide | 27 | $209 | $8 |
| Hydralazine | 12 | $179 | $15 |
| Cyclobenzaprine | 16 | $139 | $9 |
| Metoclopramide | 12 | $132 | $11 |
| Furosemide | 12 | $98 | $8 |
| Hydroxyzine | 11 | $92 | $8 |
2022: 36 drugs
| Januvia | 38 | $47,731 | $1,256 |
| Rybelsus | 14 | $12,953 | $925 |
| Linzess | 12 | $8,301 | $692 |
| Gabapentin | 63 | $2,581 | $41 |
| Atorvastatin | 90 | $1,409 | $16 |
| Metformin | 85 | $1,170 | $14 |
| Losartan | 77 | $927 | $12 |
| Omeprazole | 46 | $842 | $18 |
| Oxybutynin Chloride | 11 | $791 | $72 |
| Nitrofurantoin Mono-Macro | 22 | $746 | $34 |
| Levothyroxine | 39 | $741 | $19 |
| Amlodipine Besylate | 88 | $671 | $8 |
| Albuterol Sulfate Hfa | 16 | $562 | $35 |
| Pregabalin | 17 | $509 | $30 |
| Benazepril | 15 | $458 | $31 |
| Famotidine | 26 | $391 | $15 |
| Simvastatin | 17 | $357 | $21 |
| Tamsulosin | 19 | $350 | $18 |
| Montelukast | 15 | $338 | $23 |
| Metoprolol | 14 | $323 | $23 |
| Fluticasone Propionate | 27 | $291 | $11 |
| Diclofenac | 11 | $288 | $26 |
| Atenolol | 11 | $272 | $25 |
| Pravastatin | 15 | $261 | $17 |
| Alendronate | 25 | $261 | $10 |
| Sertraline | 13 | $247 | $19 |
| Metoprolol | 12 | $214 | $18 |
| Lisinopril | 20 | $183 | $9 |
| Hydroxyzine | 16 | $183 | $11 |
| Ondansetron | 14 | $133 | $9 |
| Sumatriptan | 11 | $117 | $11 |
| Glipizide | 23 | $102 | $4 |
| Hydrochlorothiazide | 27 | $100 | $4 |
| Trazodone | 13 | $86 | $7 |
| Fluoxetine | 11 | $75 | $7 |
| Cyclobenzaprine | 11 | $29 | $3 |
2021: 25 drugs
| Trulicity | 26 | $31,640 | $1,217 |
| Januvia | 13 | $14,517 | $1,117 |
| Lamictal | 12 | $8,173 | $681 |
| Linzess | 12 | $5,909 | $492 |
| Bystolic | 13 | $2,028 | $156 |
| Atorvastatin | 66 | $895 | $14 |
| Albuterol Sulfate Hfa | 19 | $837 | $44 |
| Gabapentin | 55 | $705 | $13 |
| Omeprazole | 51 | $691 | $14 |
| Diclofenac | 17 | $434 | $26 |
| Nitrofurantoin Mono-Macro | 16 | $434 | $27 |
| Pregabalin | 12 | $429 | $36 |
| Levothyroxine | 21 | $382 | $18 |
| Losartan | 34 | $312 | $9 |
| Amlodipine Besylate | 44 | $288 | $7 |
| Famotidine | 16 | $232 | $15 |
| Quetiapine | 13 | $226 | $17 |
| Ondansetron | 17 | $216 | $13 |
| Fluticasone Propionate | 18 | $199 | $11 |
| Alendronate | 14 | $154 | $11 |
| Metformin | 18 | $133 | $7 |
| Lisinopril | 17 | $84 | $5 |
| Hydrochlorothiazide | 26 | $81 | $3 |
| Lorazepam | 11 | $65 | $6 |
| Glipizide | 11 | $51 | $5 |
2020: 18 drugs
| Linzess | 15 | $6,883 | $459 |
| Nitrofurantoin Mono-Macro | 14 | $1,338 | $96 |
| Gabapentin | 43 | $682 | $16 |
| Albuterol Sulfate Hfa | 12 | $526 | $44 |
| Diclofenac | 18 | $522 | $29 |
| Atorvastatin | 31 | $410 | $13 |
| Omeprazole | 45 | $321 | $7 |
| Fluticasone Propionate | 21 | $295 | $14 |
| Levothyroxine | 15 | $270 | $18 |
| Benazepril | 11 | $186 | $17 |
| Amlodipine Besylate | 30 | $183 | $6 |
| Pregabalin | 12 | $169 | $14 |
| Losartan | 19 | $167 | $9 |
| Metformin | 13 | $114 | $9 |
| Lisinopril | 12 | $88 | $7 |
| Hydrochlorothiazide | 15 | $72 | $5 |
| Famotidine | 15 | $55 | $4 |
| Ibuprofen | 11 | $46 | $4 |
2019: 3 drugs
| Levothyroxine | 22 | $259 | $12 |
| Gabapentin | 13 | $128 | $10 |
| Losartan | 11 | $59 | $5 |
2018: 5 drugs
| Lantus | 15 | $4,072 | $271 |
| Terazosin | 11 | $116 | $11 |
| Pantoprazole | 13 | $72 | $6 |
| Furosemide | 14 | $51 | $4 |
| Metformin | 11 | $33 | $3 |
2017: 25 drugs
| Januvia | 11 | $7,898 | $718 |
| Advair Diskus | 11 | $4,685 | $426 |
| Lantus | 11 | $2,986 | $271 |
| Omega-3 Acid Ethyl Esters | 14 | $1,250 | $89 |
| Gabapentin | 50 | $1,002 | $20 |
| Pravastatin | 28 | $565 | $20 |
| Levothyroxine | 20 | $505 | $25 |
| Tamsulosin | 14 | $447 | $32 |
| Metformin | 57 | $390 | $7 |
| Glipizide | 41 | $287 | $7 |
| Oxybutynin Chloride | 15 | $258 | $17 |
| Losartan | 26 | $209 | $8 |
| Benazepril | 11 | $202 | $18 |
| Atorvastatin | 15 | $173 | $12 |
| Atenolol | 21 | $172 | $8 |
| Lisinopril | 44 | $167 | $4 |
| Pantoprazole | 18 | $166 | $9 |
| Simvastatin | 32 | $143 | $4 |
| Amlodipine Besylate | 25 | $140 | $6 |
| Hydrochlorothiazide | 20 | $131 | $7 |
| Omeprazole | 21 | $124 | $6 |
| Hydroxyzine | 12 | $113 | $9 |
| Fluticasone Propionate | 12 | $104 | $9 |
| Metoprolol | 13 | $94 | $7 |
| Famotidine | 14 | $69 | $5 |
2016: 33 drugs
| Januvia | 14 | $8,597 | $614 |
| Advair Diskus | 14 | $6,947 | $496 |
| Lantus | 20 | $5,833 | $292 |
| Crestor | 12 | $4,699 | $392 |
| Lantus Solostar | 14 | $1,748 | $125 |
| Fluoxetine | 13 | $1,314 | $101 |
| Omega-3 Acid Ethyl Esters | 16 | $1,062 | $66 |
| Gabapentin | 47 | $949 | $20 |
| Tamsulosin | 16 | $851 | $53 |
| Pravastatin | 33 | $820 | $25 |
| Levothyroxine | 23 | $754 | $33 |
| Glipizide | 45 | $642 | $14 |
| Metformin | 54 | $519 | $10 |
| Hydrocodone-Acetaminophen | 29 | $435 | $15 |
| Losartan | 30 | $375 | $13 |
| Atorvastatin | 13 | $324 | $25 |
| Omeprazole | 50 | $296 | $6 |
| Enalapril Maleate | 13 | $274 | $21 |
| Atenolol | 27 | $243 | $9 |
| Fluticasone Propionate | 21 | $237 | $11 |
| Oxybutynin Chloride | 12 | $230 | $19 |
| Lisinopril | 35 | $230 | $7 |
| Metoprolol | 39 | $209 | $5 |
| Amlodipine Besylate | 24 | $208 | $9 |
| Simvastatin | 31 | $199 | $6 |
| Alendronate | 14 | $184 | $13 |
| Hydrochlorothiazide | 23 | $176 | $8 |
| Clopidogrel | 13 | $175 | $13 |
| Ranitidine | 17 | $169 | $10 |
| Trazodone | 16 | $154 | $10 |
| Naproxen | 18 | $100 | $6 |
| Furosemide | 13 | $73 | $6 |
| Famotidine | 17 | $65 | $4 |
2015: 25 drugs
| Lyrica | 14 | $4,876 | $348 |
| Lantus | 13 | $4,485 | $345 |
| Pravastatin | 30 | $1,019 | $34 |
| Atorvastatin | 29 | $723 | $25 |
| Levothyroxine | 21 | $580 | $28 |
| Metformin | 70 | $580 | $8 |
| Glyburide | 12 | $477 | $40 |
| Gabapentin | 24 | $465 | $19 |
| Amlodipine Besylate | 66 | $461 | $7 |
| Tamsulosin | 18 | $430 | $24 |
| Fluticasone Propionate | 39 | $389 | $10 |
| Omeprazole | 37 | $237 | $6 |
| Simvastatin | 42 | $235 | $6 |
| Losartan | 28 | $195 | $7 |
| Metoprolol | 40 | $195 | $5 |
| Atenolol | 30 | $184 | $6 |
| Lisinopril | 29 | $171 | $6 |
| Oxybutynin Chloride | 11 | $163 | $15 |
| Hydrochlorothiazide | 33 | $130 | $4 |
| Pantoprazole | 12 | $89 | $7 |
| Clopidogrel | 14 | $66 | $5 |
| Alendronate | 13 | $63 | $5 |
| Tramadol | 12 | $62 | $5 |
| Trazodone | 11 | $56 | $5 |
| Ibuprofen | 11 | $45 | $4 |
2014: 7 drugs
| Humalog | 13 | $4,727 | $364 |
| Amlodipine Besylate | 33 | $279 | $8 |
| Metformin | 23 | $250 | $11 |
| Hydrochlorothiazide | 14 | $172 | $12 |
| Lisinopril | 19 | $144 | $8 |
| Simvastatin | 17 | $118 | $7 |
| Atenolol | 15 | $107 | $7 |
Money from drug and device companies
$43 in 2019
A payment is not proof that care is biased.
| Pfizer | Eucrisa | $27 | 1 payment
|
| Seqirus USA | Fluad | $15 | 1 payment
|
See all 2 published payments
| Pfizer | Meals · 2019-08-29 | Eucrisa | $27 |
| Seqirus USA | Meals · 2019-03-01 | Fluad | $15 |
Professional record
- NPI
- 1003080243
- Licence
- CA A99796California A99796: Current · expires 2028-08-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 1333 Meridian Ave, San Jose, CA, 95125
- NPI first listed
- 2008-04-18
- NPI last updated
- 2015-03-03
This is when the NPI record was last certified, not a medical board exam.